Entrada Therapeutics (TRDA) Current Deferred Revenue (2023 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Current Deferred Revenue of $254000.0 for Q1 2026, down 81.21% year-over-year from $1.4 million in Q1 2025, and down 25.73% quarter-over-quarter from $342000.0 in Q4 2025.
Entrada Therapeutics (TRDA) Current Deferred Revenue (2023 - 2026) Analysis & Trends
Entrada Therapeutics' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $254000.0 for Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 81.21% year-over-year to $254000.0; the TTM figure through Mar 2026 stood at $254000.0 (down 81.21% YoY), while the FY2025 annual figure was $342000.0, down 94.75% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $254000.0, down from $342000.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $148.4 million in Q3 2023, with the low at $254000.0 in Q1 2026.
- The 4-year median for Current Deferred Revenue is $8.0 million (2024), against an average of $39.1 million.
- The sharpest annual moves came in 2025 and 2026: Current Deferred Revenue plunged 95.59% in 2025, then plunged 81.21% in 2026.
- Entrada Therapeutics' Current Deferred Revenue stood at $132.3 million in 2023, then sank by 95.08% to $6.5 million in 2024, then sank by 94.75% to $342000.0 in 2025, then dropped by 25.73% to $254000.0 in 2026.
- Business Quant data shows TRDA's Current Deferred Revenue at $254000.0 in Q1 2026, $342000.0 in Q4 2025, and $351000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 173,000.00 |
| Mar 31, 2026 | 254,000.00 |
| Dec 31, 2025 | 342,000.00 |
| Sep 30, 2025 | 351,000.00 |
| Jun 30, 2025 | 689,000.00 |
| Mar 31, 2025 | 1.35 Mn |
| Dec 31, 2024 | 6.51 Mn |
| Sep 30, 2024 | 7.96 Mn |
| Jun 30, 2024 | 10.35 Mn |
| Mar 31, 2024 | 9.41 Mn |
| Dec 31, 2023 | 132.26 Mn |
| Sep 30, 2023 | 148.44 Mn |
| Jun 30, 2023 | 101.65 Mn |
| Mar 31, 2023 | 89.24 Mn |